Health Canada validates SCENESSE New Drug Submission
Filed with ASX · · 2 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Chair's letter to Shareholders
- SCENESSE dosage expansion under review by EMA
- CLINUVEL prioritises three strategic programs
- Managing Director Presentation
- Canadian New Drug Submission for SCENESSE in EPP filed
Later from Clinuvel Pharmaceuticals
- Vitiligo - CUV105 Study Update
- Preliminary results from SCENESSE adolescent EPP study
- Half Year Results Announcement
- Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
- Positive preliminary results for PRENUMBRA Instant in stroke
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals